You are here: Industry Insights > Mylan

News List

Mylan and Pfizer delay Upjohn merger amid coronavirus pandemic pharmaceutical-technology
March 30, 2020
Mylan’s merger with Pfizer’s off-patent branded drugs unit Upjohn is now expected to close in the second half of this year due to the coronavirus pandemic.
Mylan and Gilead waive exclusivity for potential Covid-19 therapies pharmaceutical-technology
March 27, 2020
Mylan has waived its exclusive rights to generic Kaletra (lopinavir / ritonavir) in the US to aid wider access in case the medication would be effective Covid-19 therapies.
Mylan Preps to Meet Potential COVID-19 Patient Needs contractpharma
March 23, 2020
To help address public health needs amidst the evolving COVID-19 pandemic, Mylan has restarted production of hydroxychloroquine sulfate tablets ...
Mylan Ramps Up U.S. Manufacturing of Hydroxychloroquine Sulfate Tablets to Meet Potential COVID-19 Patient Needs PRNewswire
March 20, 2020
Mylan N.V. (NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic.
Biocon, Mylan win patent litigation for Insulin Glargine device patent in the US expresspharma
March 12, 2020
Brings Biocon closer to commercialising Semglee in the US in 2020.
FDA Accepts BLA for Proposed Biosimilar Bevacizumab for Review americanpharmaceuticalreview
March 10, 2020
Mylan and Biocon announced the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1402O, a proposed biosimilar to Avastin® (bevacizumab), for review under the 351(k) pathway.
Mylan Recalls Three Lots of Nizatidine Capsules americanpharmaceuticalreview
January 14, 2020
Mylan announced its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall, to the consumer level, of three lots of Nizatidine Capsules, USP (including the 150mg and 300mg strengths).
Mylan, Biocon Launch Trastuzumab Biosimilar, Ogivri in the U.S. americanpharmaceuticalreview
December 30, 2019
Mylan and Biocon announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab).
Pfizer, Mylan Announce Two Future Viatris Board Members americanpharmaceuticalreview
December 20, 2019
Pfizer and Mylan announced Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination of Mylan N.V. and Upjohn Inc. ...
Eisai, Mylan to promote anti-cancer drug brands in India biospectrumasia
September 23, 2019
Eisai group positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page